Characteristics of patients in the different conditioning groups
| Parameter . | MAC (n = 165) . | RIC (n = 143) . | NMAC (n = 88) . | P . |
|---|---|---|---|---|
| Median age, y (range) | 48 (18-66) | 54 (20-69) | 54 (19-69) | < .001 |
| Age group at alloHCT, y | ||||
| 18-29 | 22 (13%) | 14 (10%) | 7 (8%) | .001 |
| 30-39 | 27 (16%) | 20 (14%) | 13 (15%) | |
| 40-49 | 49 (30%) | 25 (17%) | 11 (13%) | |
| 50-59 | 58 (35%) | 55 (38%) | 35 (40%) | |
| 60-64 | 7 (4%) | 23 (16%) | 16 (18%) | |
| Male sex | 97 (59%) | 87 (61%) | 44 (50%) | .248 |
| Karnofsky score at alloHCT < 90 | 63 (38%) | 56 (39%) | 36 (41%) | .977 |
| Lymphoma stage at diagnosis | ||||
| I-II | 42 (25%) | 44 (31%) | 34 (39%) | .007 |
| III-IV | 118 (72%) | 85 (59%) | 45 (51%) | |
| Missing | 5 (3%) | 14 (10%) | 9 (10%) | |
| BM involvement at diagnosis | 43 (26%) | 35 (24%) | 14 (16%) | .039 |
| B symptoms at diagnosis | 75 (45%) | 38 (27%) | 22 (25%) | |
| No. of chemotherapy lines before alloHCT | ||||
| 1 | 4 (2%) | 4 (3%) | 2 (2%) | .002 |
| 2 | 41 (25%) | 24 (17%) | 6 (7%) | |
| 3 | 38 (23%) | 25 (17%) | 18 (20%) | |
| 4 | 33 (20%) | 45 (31%) | 32 (36%) | |
| 5 | 40 (24%) | 34 (24%) | 30 (34%) | |
| Missing | 9 (6%) | 11 (8%) | 0 | |
| Radiation before alloHCT | 53 (32%) | 68 (48%) | 44 (50%) | .005 |
| Rituximab before alloHCT | 106 (64%) | 96 (67%) | 64 (73%) | .392 |
| Prior autologous HCT | 29 (18%) | 51 (36%) | 45 (51%) | < .001 |
| Disease status before transplantation | ||||
| PIF-sensitive | 35 (21%) | 14 (10%) | 7 (8%) | < .001 |
| PIF-resistant | 41 (25%) | 21 (15%) | 6 (7%) | |
| Relapse-sensitive | 32 (19%) | 36 (25%) | 24 (27%) | |
| Relapse-resistant | 28 (17%) | 22 (15%) | 17 (19%) | |
| CR2+ | 19 (12%) | 34 (24%) | 30 (34%) | |
| Relapse untreated/unknown | 2 (1%) | 3 (2%) | 1 (1%) | |
| Missing | 8 (5%) | 13 (9%) | 3 (3%) | |
| Median interval from diagnosis to alloHCT, mo (range) | 17 (4-238) | 27 (5-309) | 36 (8-198) | < .001 |
| Interval between diagnosis and alloHCT, mo | ||||
| < 12 | 49 (30%) | 18 (13%) | 8 (9%) | < .001 |
| 12-24 | 58 (35%) | 44 (31%) | 21 (24%) | |
| 24-36 | 16 (10%) | 24 (17%) | 15 (17%) | |
| 36-60 | 15 (9%) | 25 (17%) | 20 (23%) | |
| > 60 | 25 (15%) | 29 (20%) | 24 (27%) | |
| Interval from autologous to allogeneic HCT, mo | ||||
| 6-12 | 12 (41%) | 15 (29%) | 10 (22%) | .263 |
| 12-24 | 12 (41%) | 17 (33%) | 17 (38%) | |
| 24-36 | 1 (3%) | 10 (20%) | 4 (9%) | |
| 36-48 | 1 (3%) | 4 (8%) | 4 (9%) | |
| 48-60 | 0 | 2 (4%) | 4 (9%) | |
| > 60 | 3 (10%) | 3 (6%) | 6 (13%) | |
| No prior autologous HCT | 136 (82%) | 92 (64%) | 43 (49%) |
| Parameter . | MAC (n = 165) . | RIC (n = 143) . | NMAC (n = 88) . | P . |
|---|---|---|---|---|
| Median age, y (range) | 48 (18-66) | 54 (20-69) | 54 (19-69) | < .001 |
| Age group at alloHCT, y | ||||
| 18-29 | 22 (13%) | 14 (10%) | 7 (8%) | .001 |
| 30-39 | 27 (16%) | 20 (14%) | 13 (15%) | |
| 40-49 | 49 (30%) | 25 (17%) | 11 (13%) | |
| 50-59 | 58 (35%) | 55 (38%) | 35 (40%) | |
| 60-64 | 7 (4%) | 23 (16%) | 16 (18%) | |
| Male sex | 97 (59%) | 87 (61%) | 44 (50%) | .248 |
| Karnofsky score at alloHCT < 90 | 63 (38%) | 56 (39%) | 36 (41%) | .977 |
| Lymphoma stage at diagnosis | ||||
| I-II | 42 (25%) | 44 (31%) | 34 (39%) | .007 |
| III-IV | 118 (72%) | 85 (59%) | 45 (51%) | |
| Missing | 5 (3%) | 14 (10%) | 9 (10%) | |
| BM involvement at diagnosis | 43 (26%) | 35 (24%) | 14 (16%) | .039 |
| B symptoms at diagnosis | 75 (45%) | 38 (27%) | 22 (25%) | |
| No. of chemotherapy lines before alloHCT | ||||
| 1 | 4 (2%) | 4 (3%) | 2 (2%) | .002 |
| 2 | 41 (25%) | 24 (17%) | 6 (7%) | |
| 3 | 38 (23%) | 25 (17%) | 18 (20%) | |
| 4 | 33 (20%) | 45 (31%) | 32 (36%) | |
| 5 | 40 (24%) | 34 (24%) | 30 (34%) | |
| Missing | 9 (6%) | 11 (8%) | 0 | |
| Radiation before alloHCT | 53 (32%) | 68 (48%) | 44 (50%) | .005 |
| Rituximab before alloHCT | 106 (64%) | 96 (67%) | 64 (73%) | .392 |
| Prior autologous HCT | 29 (18%) | 51 (36%) | 45 (51%) | < .001 |
| Disease status before transplantation | ||||
| PIF-sensitive | 35 (21%) | 14 (10%) | 7 (8%) | < .001 |
| PIF-resistant | 41 (25%) | 21 (15%) | 6 (7%) | |
| Relapse-sensitive | 32 (19%) | 36 (25%) | 24 (27%) | |
| Relapse-resistant | 28 (17%) | 22 (15%) | 17 (19%) | |
| CR2+ | 19 (12%) | 34 (24%) | 30 (34%) | |
| Relapse untreated/unknown | 2 (1%) | 3 (2%) | 1 (1%) | |
| Missing | 8 (5%) | 13 (9%) | 3 (3%) | |
| Median interval from diagnosis to alloHCT, mo (range) | 17 (4-238) | 27 (5-309) | 36 (8-198) | < .001 |
| Interval between diagnosis and alloHCT, mo | ||||
| < 12 | 49 (30%) | 18 (13%) | 8 (9%) | < .001 |
| 12-24 | 58 (35%) | 44 (31%) | 21 (24%) | |
| 24-36 | 16 (10%) | 24 (17%) | 15 (17%) | |
| 36-60 | 15 (9%) | 25 (17%) | 20 (23%) | |
| > 60 | 25 (15%) | 29 (20%) | 24 (27%) | |
| Interval from autologous to allogeneic HCT, mo | ||||
| 6-12 | 12 (41%) | 15 (29%) | 10 (22%) | .263 |
| 12-24 | 12 (41%) | 17 (33%) | 17 (38%) | |
| 24-36 | 1 (3%) | 10 (20%) | 4 (9%) | |
| 36-48 | 1 (3%) | 4 (8%) | 4 (9%) | |
| 48-60 | 0 | 2 (4%) | 4 (9%) | |
| > 60 | 3 (10%) | 3 (6%) | 6 (13%) | |
| No prior autologous HCT | 136 (82%) | 92 (64%) | 43 (49%) |
IPI indicates international prognostic index; PIF, primary induction failure; REL, relapse; and CR, complete remission.